A5101704338- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Inflammatory Biomarkers in Disease Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Brain Metastases and Treatment
- Pancreatic and Hepatic Oncology Research
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Genetic factors in colorectal cancer
- Cancer, Lipids, and Metabolism
- Peptidase Inhibition and Analysis
- Cancer, Hypoxia, and Metabolism
- PI3K/AKT/mTOR signaling in cancer
- RNA modifications and cancer
- Cytokine Signaling Pathways and Interactions
- Hepatocellular Carcinoma Treatment and Prognosis
- Heat shock proteins research
- Myasthenia Gravis and Thymoma
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Medicinal Plant Pharmacodynamics Research
Tumor Hospital of Guangxi Medical University
2012-2025
Guangxi Medical University
2014-2024
IntroductionSintilimab, an anti–programmed death 1 antibody, plus pemetrexed and platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We conducted randomized, double-blind, 3 study to compare the safety of sintilimab with placebo, both combination such chemotherapy (ClinicalTrials.gov: NCT03607539).MethodsA total 397 patients previously untreated, locally advanced or metastatic without sensitizing EGFR anaplastic lymphoma kinase genomic aberration were...
IntroductionSintilimab plus chemotherapy significantly prolonged progression-free survival (PFS) compared with alone in nonsquamous NSCLC the ORIENT-11 study. Updated overall (OS) and PFS data corresponding biomarker analyses are reported here.MethodsIn this study, a total of 397 patients previously untreated, locally advanced or metastatic were assigned to sintilimab combination treatment (combo) group placebo group. The stratified by programmed death-ligand 1 (PD-L1) expression levels....
Background This study aimed to evaluate the antitumor activity of camrelizumab, an antiprogrammed cell death-1 antibody, in pretreated recurrent or metastatic nasopharyngeal carcinoma (NPC) and explore predictive biomarkers. Methods Patients with (not amenable locally curative treatment) NPC who had failed at least two lines chemotherapy were eligible receive camrelizumab (200 mg intravenously every 2 weeks) for years until disease progression, intolerable adverse events, withdrawal...
Although first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy is effective for treating EGFR-mutant non–small cell lung cancer (NSCLC), it now understood that drug-tolerant persister (DTP) cells escaping from initial treatment eventually drives drug resistance. Here, through integration of metabolomics and transcriptomics, we found the neurotransmitter acetylcholine (ACh) was specifically accumulated in DTP cells, demonstrated with EGFR-TKI heightened...
This study aimed to evaluate the efficacy and safety of cadonilimab (anti PD-1 CTLA-4 bispecific antibody) in patients with previously treated metastatic non-small-cell lung cancer (NSCLC).In this multicenter, open-label, phase Ib/II study, NSCLC were enrolled three different cohorts: Cohort A, who had failed previous platinum-based doublet chemotherapy immunotherapy naïve; B, primary resistance (IO); C, acquired IO. Eligible given 6 mg/kg intravenously every 2 weeks. The endpoint was...
Endostar™ (rh-endostatin, YH-16) is a new recombinant human endostatin developed by Medgenn Bioengineering Co. Ltd., Yantai, Shandong, P.R.China. Pre-clinical study indicated that YH-16 could inhibit tumor endothelial cell proliferation, angiogenesis and growth. Phase I phase II studies revealed was effective as single agent with good tolerance in clinical use.The current to compare the response rate , median ti me progression (TTP) ,clinical benefit andsafety patients advanced non-small...
Abstract Background Furmonertinib (AST2818) is a brain penetrant pan-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting both EGFR sensitizing mutations and T790M mutation. We report the pooled central nervous system (CNS) efficacy data of furmonertinib in patients with mutated non-small cell lung cancer (NSCLC) from two phase 2 studies. Methods This was pooled, post-hoc analysis studies (NCT03127449 [phase 2a study furmonertinib], NCT03452592 2b...
Befotertinib (D-0316) is a novel, third-generation EGFR tyrosine kinase inhibitor (TKI). This study evaluated befotertinib in patients with locally advanced or metastatic NSCLC who developed an T790M mutation after progression on first- second-generation TKI therapy.This was single-arm, open-label, phase 2 at 49 hospitals across mainland China. Patients harboring mutations disease prior therapy received oral of 50 mg (cohort A) 75 to 100 B) once daily. The primary end point objective...
Background: Programmed cell death protein-1/programmed protein-ligand 1 (PD-1/PD-L1) inhibitor and chemotherapy are the standard treatment for advanced non-small lung cancer (NSCLC) without sensitizing mutations. However, patients with untreated, symptomatic or recently-irradiated brain metastases (BMs) mostly excluded from immunochemotherapy trials. This study aims to evaluate intracranial response pattern, tolerability biomarkers of tislelizumab plus in NSCLC BM.
3106 Background: Lung cancer is the leading cause for all cancer-related death, with NSCLC accounting 85% of cases. The oncogenic RET-fusion identified in 1-2% patients. Several RET inhibitors have been approved. This pivotal phase II study aimed to evaluate efficacy and safety SY-5007, a novel, highly selective inhibitor, Chinese patients advanced, positive NSCLC. Methods: trial enrolled two cohorts Cohort 1 comprised treatment-naive patients, cohort 2 included those previously treated...
Evidence regarding the relationship between albumin-to-alkaline phosphatase ratio (AAPR) and overall survival (OS) in extensive-disease small-cell lung cancer (ED-SCLC) patients is limited. This study aimed to investigate whether AAPR was independently related OS ED-SCLC after adjusting for potential covariates.This a retrospective cohort of 224 with ED-SCLC. The target independent dependent variables were pretreatment OS, respectively. Covariates included age; sex; Eastern Cooperative...
Our aim was to evaluate the efficacy and safety of inetetamab plus chemotherapy in first-line treatment HER2-positive metastatic breast cancer.
Abstract EML4‐ALK fusion genes have been recognized as novel “driver mutations” in a small subset of non‐small cell lung cancers (NSCLC). The frequency fusions NSCLC patients who clinical characteristics related to EGFR mutation remains unknown. We screened 102 Chinese with based on one or more the following characteristics: female, no light smoking history, and adenocarcinoma histology. were identified by RT‐PCR, whereas (Exons 18–21) KRAS 1 2) mutations detected DNA sequencing. Eight...
The aim of this study was to assessment the efficacy and safety Programmed cell death protein 1 (PD-1)/Programmed death-Ligand (PD-L1) inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 as second later-line treatment for patients advanced non-small lung cancer.In study, pre-treatment clinical laboratory indicators from 73 cancer were retrieved retrospective analysis. According therapy regimes they received, separated into groups, group (PC group), agents'...